Specifically, MenABCWY produced strong immune responses against a panel of 110 diverse MenB strains, covering 95% of the circulating strains in the US It was well tolerated, with no major safety concerns, and demonstrated a robust immune response across all five meningococcal serogroups (A, B, C, W, and Y). These results position MenABCWY as a significant tool in reducing the incidence of invasive meningococcal disease, particularly among adolescents and young adults at higher risk.2
MenABCWY is administered as two intramuscular (IM) injections, given six months apart, following a dosing regimen similar to Penbraya. The approval of MenABCWY is expected to enhance protection for primary care and pediatric populations, providing an effective option to prevent meningococcal disease in a broader age group.1
In the press release, Tony Wood, chief scientific officer at GSK, said, “We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by serogroup B. Building on our global leadership in meningococcal vaccination and our longstanding commitment to address unmet need in disease prevention, we aim to help protect more teens and young adults at a life stage when they are at an increased risk.”1
What You Need To Know
GSK's Penmenvy vaccine has been FDA-approved for individuals aged 10-25 to protect against five meningococcal serogroups (A, B, C, W, and Y).
MenABCWY, combining elements of Bexsero and Menveo, showed strong immune responses and met all primary endpoints in its Phase 3 trial.
The approval of MenABCWY provides enhanced protection against meningococcal disease for adolescents and young adults, especially in high-risk settings like dormitories.
IMD is a serious, often rapidly progressing disease that can lead to death in as little as 24 hours. It is frequently misdiagnosed in its early stages, as its symptoms can resemble those of the flu,1 but can lead to deadly infections like meningitis (brain and spinal cord inflammation) and bloodstream infections.3 Adolescents and young adults, especially those in close living environments such as dormitories, are at higher risk for contracting the disease.1
The CDC's Advisory Committee on Immunization Practices (ACIP) will meet on February 26, 2025, to discuss recommendations for the vaccine's use in the target age group.1
References
1. GSK. PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA. February 14, 2025. Accessed February 14, 2025. https://us.gsk.com/en-us/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/
3. Centers for Disease Control and Prevention. Meningococcal Disease. Centers for Disease Control and Prevention. Updated February 1, 2024. Accessed February 14, 2025. 2025.https://www.cdc.gov/meningococcal/about/index.html